Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Tuesday that its fourth quarter revenues rose 107 percent year over year, thanks to a 63 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

For the three months ended Dec. 31, 2019, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $295.6 million, up from $143.0 million a year earlier, and beating the average Wall Street estimate of $283.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.